Navigating the orphan medicinal product designation: Evidence requirements for gene therapies in Europe

Area of Science:

• Gene Therapy
• Rare Diseases
• Regulatory Science

Background:

• Orphan designation is crucial for rare disease drug development.
• Viral vector-mediated gene therapies offer potential for rare conditions.
• Understanding regulatory decision-making provides insights into drug development pathways.

Purpose of the Study:

• To analyze data submitted for orphan designation of viral vector-mediated gene therapies.
• To understand regulatory decision-making by the Committee for Orphan Medicinal Products.
• To identify trends in preclinical and clinical data for successful applications.

Main Methods:

• Retrospective analysis of applications for orphan designation.
• Focus on viral vector-mediated gene therapies for rare non-oncological conditions.
• Evaluation of data supporting regulatory criteria.

Main Results:

• High proportion of non-clinical in vivo data submitted, indicating early-stage (preclinical) development.
• Clinical data present in only 13% of applications, often preliminary.
• Mouse models frequently used for proof-of-concept; surrogate endpoints common.
• Significant benefit criterion applicable in 54% of submissions, showing focus on unmet needs.

Conclusions:

• Early-stage, preclinical data, particularly from in vivo studies, dominates gene therapy orphan designation applications.
• Sponsors prioritize gene therapy development for rare diseases with high unmet medical needs and limited existing treatments.
• Regulatory insights highlight the importance of robust non-clinical data for early-stage gene therapy development.